Products / Other therapeutic lines

Yriviak

Bevacizumab 5 mg/0,2 ml

Yriviak is indicated for the treatment of adult patients with neovascular (exudative) age-related macular degeneration (AMD).

Therapeutic Action

Antiangiogenic agent, monoclonal antibody.

Presentations

Package with 1 vial containing 0.2 ml (5 mg) of bevacizumab solution and the following sterile disposable medical products: extraction filter needle (18G X 1½”, 1.2 mm x 40 mm, 5 µm filter), 1 ml syringe and injection needle (30G x ½”, 0.3 mm x 13 mm).

Yriviak Bevacizumab 5 mg/0,2 ml de Laboratorios Richmond
Download Prospect

Legal Notice

Products which continue to have a valid patent protection at present are manufactured in line with the current laws of the Argentine Republic. Please, take into account that our products will only be shipped to countries where the substance and its use are not protected by patents.

Laboratorios Richmond S.A.C.I.F. Argentina © All rights reserved Terms of use